CA Corresponding Author Ã These authors contributed equally to this study EVIDENCE suggests that cannabinoid receptors, the pharmacologcial target of cannabis-derived drugs, and their accompanying system of endogenous activators may be dysfunctional in schizophrenia. To test this hypothesis, we examined whether endogenous cannabinoid concentrations in cerebrospinal¯uid of schizophrenic patients are altered compared to nonschizophrenic controls. Endogenous cannabinoids were puri®ed from cerebrospinal¯uid of 10 patients with schizophrenia and 11 non-schizophrenic controls by high-performance liquid chromatography, and quanti-®ed by isotope dilution gas-chromatography/massspectrometry. Cerebrospinal concentrations of two endogenous cannabinoids (anandamide and palmitylethanolamide) were signi®cantly higher in schizophrenic patients than non-schizophrenic controls ( p , 0.05). By contrast, levels of 2-arachidonylglycerol, another endogenous cannabinoid lipid, were below detection in both groups. The ®ndings did not seem attributable to gender, age or medication. Elevated anandamide and palmitylethanolamide levels in cerebrospinal¯uid of schizophrenic patients may re¯ect an imbalance in endogenous cannabinoid signaling, which may contribute to the pathogenesis of schizophrenia. NeuroReport 10:1665±1669 # 1999 Lippincott Williams & Wilkins.
Introduction
Progress in the treatment of schizophrenia has been hindered by an inadequate understanding of the pathogenesis of this disease and of the mechanisms by which drugs that block D 2 -family dopamine receptors mitigate its symptoms. Although dopamine neurotransmission is thought to be abnormal in schizophrenia, D 2 -blocking drugs are only partially effective in preventing its diverse manifestations [1] . Thus alterations in other brain signaling pathways have been postulated, and hypotheses on the causation of schizophrenia extended to include interactions among multiple neurotransmitter systems in addition to dopamine (for review see [2] ). However, despite the urgent need for improved antipsychotic therapies, the nature of these transmitter interactions is still largely unknown. Several lines of evidence suggest that schizophrenia may be associated with anomalies in the function of cannabinoid receptors and their attendant system of endogenous activators. Cannabinoid receptors are the pharmacological target of marijuana and hashish, cannabis-derived drugs that contain Ä 9 -tetrahydrocannabinol (Ä 9 -THC) (for review see [3] ). Preva-lence of cannabis consumption is signi®cantly higher among schizophrenics than normal individuals [4] , and prolonged abuse of large quantities of cannabis may trigger relapse of psychotic symptoms in schizophrenic patients [5, 6] . These phenomena, though unexplained at the molecular level, are consistent with the neuroanatomical distribution of cannabinoid receptors. Indeed some of the highest densities of these receptors are found in regions of the human brain that have been implicated in schizophrenia, including prefrontal cortex, basal ganglia, hippocampus and anterior cingulate cortex [7] . Similarities between certain cognitive impairments occurring in psychoses and the pharmacological effects of Ä 9 -THC have also been documented [8, 9] .
Additional support for a role of cannabinoid signaling in schizophrenia comes from the existence of functional interactions between dopamine and anandamide (arachidonylethanolamide), an endogenous cannabinoid compound [10, 11] . Microdialysis experiments have shown that anandamide release in rat dorsal striatum is dramatically stimulated by activation of D 2 -family, but not D 1 -family dopamine receptors [12] . The physiological signi®cance of this effect is still unresolved, but behavioral experiments indicate that anandamide may act as a local modulatory signal to offset dopamine-induced psychomotor activation [12] . Along with anandamide, brain neurons produce two additional lipids that have been involved in cannabinoid signaling: 2arachidonylglycerol (2-AG) [13±15] and palmitylethanolamide (PEA) [16] . Neither compound appears to be released by D 2 -family receptor activation in vivo, however, pointing to a speci®c role for anandamide in this response [12] .
To reveal possible abnormalities of endogenous cannabinoid signaling in schizophrenia, we have measured endogenous cannabinoid levels in cere-brospinal¯uid (CSF) of schizophrenic patients and non-schizophrenic controls by using a combination of high-performance liquid chromatography (HPLC) and gas-chromatography/mass spectrometry (GC/MS) techniques, which provide the high degree of sensitivity and selectivity needed to accomplish this task.
Materials and Methods
Patients and controls: Ten patients with acute schizophreniform psychotic symptoms were included in our study. Nine patients ful®lled the diagnostic criteria from DSM-IV [17] for schizophrenia and one for schizophreniform psychosis (due to limited observation time). Patient characteristics are summarized in Table 1 . Four patients had a history of intermittent consumption of cannabis resin and/or alcohol, but did not match the diagnostic criteria for acute intoxication, drug dependence or withdrawal syndrome. Schizophrenic symptoms lasted at least 4 months in all patients. Psychopathological disturbance was additionally quanti®ed using the seven step Brief Psychiatric Rating Scale (BPRS) [18] . BPRS scores re¯ecting the psychopathological condition at the time of lumbar puncture are provided in Table 1 . All CSF samples were collected for diagnostic purposes. Patients were informed that the rest of the samples would be stored and used for further research investigations. The mean age of the patients (seven male, three female) at the time of examination was 27.7 years (s.d. 9.6). Control subjects were a group of 11 age-matched subjects free of diagnosable psychopathology according to DSM-IV criteria. CSF was obtained for neurological differential diagnoses, revealing no signi®cant pathological ®ndings. All patients and subjects gave informed consent according to the Declaration of Helsinki.
CSF investigations: Lumbar punctures were done around noon, with the subjects in lying position and the needle inserted in the lumbar 4±5 interspace. An Table 1 . Clinical characteristics of patients participating in the study No. ) . These standards were added to CSF samples (1.2 nmol in 15 ml) to improve recovery and allow for quantitative measurements. The CSF samples were divided into three aliquots of 5 ml, subjected to acetone precipitation of proteins and centrifuged for 10 min at room temperature (800 3 g). The supernatants were collected and their volumes reduced under a stream of N 2 . Lipids were extracted with chloroform/methanol (2:1, vol/vol). Chloroform phases were evaporated to dryness, reconstituted in chloroform (150 ìl) and fractionated by normal-phase HPLC [20] . Analytes of interest were collected in glass reaction vessels, brought to dryness and converted to trimethylsilylethers by treatment with BSTFA (30 min at room temperature). Details on the isotope dilution GC/MS methods are provided elsewhere [20] . Concentrations of analytes in CSF samples are expressed as pmol/ml and were calculated by averaging three separate determinations for each 5 ml sample. Statistical signi®cance was determined by Student's t-test. Sample storage did not affect analysis, as no signi®cant differences in endogenous cannabinoid concentrations were found between two groups of non-schizophrenic CSF samples kept at À808C for 4 years (n 5) or 2 months (n 5) (data not shown).
Age

Results
CSF investigations: Normal cell counts were found for all subjects except for one schizophrenic with a marginal elevation to 6.0 cells/ìl, and one control with 6.3 cells/ìl. The CSF/serum albumin quotient, which is considered a measure of the blood±CSF barrier function, was also normal (, 7.4), apart from one control with a slight increase to 8.6. The IgG index was always below 0.700 and no oligoclonal bands were found in either group by isoelectric focusing, indicating the absence of intrathecal IgG synthesis. Extensive virological and microbiological testing gave negative results.
Endogenous cannabinoid analyses: Figure 1A expected for anandamide and other fatty acylethanolamides. As shown in Fig. 1B , an m/z 404 fragment co-eluted with authentic anandamide, while m/z 356 and m/z 382 fragments co-eluted with PEA and oleylethanolamide, respectively (data not shown).
These results indicate that anandamide and other fatty acylethanolamides are present in human CSF.
We quanti®ed these lipid compounds using an isotope dilution method [21] . Deuterium-containing acylethanolamide standards were included in CSF samples and both native and deuterated [M-15] ions were monitored by GC/MS (Fig. 1B) . CSF concentrations were calculated from the native-todeuterated ion ratio by using calibration curves generated with synthetic standards. In schizophrenic patients, average anandamide and PEA levels were ,2-fold higher than in controls ( Fig. 2A,B ; p , 0.05, Student's t-test). Eleven control subjects had anandamide levels of 0.30 AE 0.29 pmol/ml and PEA levels of 1.80 AE 0.83 pmol/ml (mean AE s.d.). Levels in 10 schizophrenic patients were 0.70 AE 0.47 pmol/ml and 3.50 AE 1.73 pmol/ml, respectively. By contrast, no difference was observed between the two groups in the levels of oleylethanolamide, an acylethanolamide that does not activate central or peripheral cannabinoid receptors (controls 0.90 AE 0.42 pmol/ml; schizophrenics 0.80 AE 0.40 pmol/ml; Fig. 2C ). In this limited patient sample, we found no obvious correlation between endogenous cannabinoid levels and age, gender, medication or drug abuse ( Table 1 ). The limited number of schizophrenic patients examined prevented the identi®cation of possible clusters of individuals differing in endogenous cannabinoid levels.
We also attempted to determine CSF levels of 2-AG, an endogenous cannabinoid that has been implicated in hippocampal neurotransmission [13± 15]. We monitored a diagnostic [M-90] fragment (m/z 432) and its deuterated counterpart (m/z 440) produced by standard [ 2 H 8 ]-2-AG. Although the limit of detection for 2-AG (1 pmol) was similar to that for anandamide (0.4 pmol) and the recoveries of internal standard were generally satisfactory, we could not detect signi®cant levels of the m/z 432 fragment in any of the samples analyzed (data not shown). These results are consonant with the lack of 2-AG release observed in rat striatum by microdialysis [12] and suggest that 2-AG concentrations are exceedingly low in CSF of both normal and schizophrenic subjects.
Discussion
We have found that CSF concentrations of anandamide and PEA, two lipid compounds that have been implicated in different aspects of endogenous cannabinoid signaling, are markedly elevated in individuals with schizophrenia compared with controls.
Since anandamide is released in rat brain by activation of D 2 -family dopamine receptors [12] , our ®ndings may re¯ect a homeostatic adaptation of the endogenous cannabinoid system to neurotransmitter imbalances that involve dopamine. Such imbalances have been postulated to occur in schizophrenia [1, 2, 22] . Alternatively, increased anandamide concentrations in CSF may re¯ect a primary`hypercannabinergic' state, which may occur in schizophrenia or in a subgroup of schizophrenic syndromes [8, 9] .
Although anandamide and PEA are produced in brain through a common biochemical mechanism [11] , PEA does not bind to CB1 cannabinoid receptors [10] and it is not released in vivo by neural activity or D 2 -receptor occupation [12] . Pharmacological evidence indicates, however, that PEA may reduce excitotoxicity in cerebellum and activate CB2-like receptors in peripheral tissues [23] . Our ®ndings, showing elevated PEA levels in schizophrenia, emphasize the need to investigate further the biochemical and pharmacological properties of this putative signaling molecule.
There are several limitations and possible confounders in our study. First, like other phospholipid metabolites, anandamide and other acylethanolamides accumulate post mortem in the central nervous system [24] . Although this phenomenon may confuse quantitative analyses in autopsy tissues, it is unlikely to account for the differences observed in CSF of schizophrenic and control subjects. In agreement with this conclusion, we found that the levels of 2-AG and oleylethanolamide, which are also increased following ischemia [24, 25] , are not changed in schizophrenia. Second, after release from neurons, anandamide is rapidly inactivated by high-af®nity uptake and enzymatic hydrolysis [11,26±28]. PEA may also be a substrate for hydrolase enzymes [26] . Thus differences in acylethanolamide levels in CSF may re¯ect changes in either release or inactivation of these compounds. Third, the neuronal origin of the acylethanolamides found in CSF remains conjectural. It is important to point out, however, that the predominant cannabinoid compound released by vascular cells is 2-AG [29±31], which was undetectable in CSF. Finally, although the apparent lack of correlation between antipsychotic drug exposure and acylethanolamide levels suggests that medication does not account for our observations, further studies will be needed to establish this point on a ®rmer basis.
Conclusion
CSF concentrations of anandamide and PEA are signi®cantly elevated in schizophrenic patients compared with non-schizophrenic controls, suggesting that functional abnormalities in endogenous cannabinoid signaling may participate in the pathogenesis of this disease. Con®rmation of our results in a larger and more diverse patient population will be instrumental not only to construct speci®c hypotheses on the possible roles of the endogenous cannabinoid system in schizophrenia, but also to suggest novel therapeutic interventions for the treatment of this disease.
